Bedford Laboratories announced that it has received approval from the Food and Drug Administration to market pamidronate(Drug information on pamidronate) disodium for injection. The product will be the only liquid version available on the market, and is equivalent to the Novartis pamidronate disodium product (Aredia), a bone resorption inhibitor indicated for the treatment of hypercalcemia associated with malignancy, for Paget’s disease, and for osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma.
"We expect hospitals to appreciate the added convenience of our presentation, which is a solution, compared to Aredia, which requires reconstitution," said Tom Murphy, a general manager at Bedford Laboratories. "Although a solution, it is entirely equivalent in function to Arediajust easier to use."
Pamidronate disodium injection will be supplied in two presentations, a 30 mg/10 mL vial and a 90 mg/10 mL vial.